Announcements Trials
Browse Landscape

Phase

Phase 1 2

Status

Completed 2Terminated 1

Sponsor Class

OTHER 2

Study Type

Interventional 2

Sponsor

Cancer Type

Other solid neoplasm 1

Conditions

Leukemia, Myelogenous, Chronic, BCR-ABL Positive 32Precursor Cell Lymphoblastic Leukemia-Lymphoma 22Leukemia 19Leukemia, Myeloid, Chronic-Phase 16Breast Neoplasms 11Neoplasm Metastasis 10Leukemia, Myeloid, Acute 8Blast Crisis 8Prostatic Neoplasms 7Neoplasms 6Carcinoma, Non-Small-Cell Lung 6Recurrence 5Pancreatic Neoplasms 5Leukemia, Myeloid, Accelerated Phase 5Leukemia, Lymphocytic, Chronic, B-Cell 5Melanoma 4Gliosarcoma 4Glioblastoma 4Rectal Neoplasms 3Philadelphia Chromosome 3Lung Neoplasms 3Glioma 3Gastrointestinal Stromal Tumors 3Colorectal Neoplasms 3Colonic Neoplasms 3Brain Neoplasms 3Sarcoma 2Salivary Gland Neoplasms 2Ovarian Neoplasms 2Myelodysplastic Syndromes 2

Interventions

Nivolumab 13Surveys and Questionnaires 6Ipilimumab 6linrodostat 5Standard of Care 5Paclitaxel 5Bevacizumab 5Sirolimus 4Pemetrexed 4Interviews as Topic 4Gemcitabine 4Docetaxel 4ARRY-334543 4temsirolimus 3relatlimab 3Erlotinib Hydrochloride 3Cetuximab 3Carboplatin 3regorafenib 2anlotinib 2abemaciclib 2Vorinostat 2Trastuzumab 2Sorafenib 2N-(3,4-difluoro-2-(2-fluoro-4-iodophenylamino)-6-methoxyphenyl)-1-(2,3-dihydroxypropyl)cyclopropane-1-sulfonamide 2Magnetic Resonance Spectroscopy 2Doxorubicin 2Dasatinib 2Cyclophosphamide 2vorolanib 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Completed × Advanced Cancer × Dasatinib × Clear all
NCT00895128 2015-07-13

Study of Erlotinib in Combination With Dasatinib

M.D. Anderson Cancer Center

Phase 1 Completed
65 enrolled

Advanced Cancer

NCT00429234 2013-04-04

Gemcitabine and Dasatinib in Advanced Solid Tumors

M.D. Anderson Cancer Center

Phase 1 Completed
54 enrolled
Other solid neoplasm

Advanced Cancer

Data powered by HemOnc (CC BY 4.0) Colophon âš¡